Jordi Rodon Ahnert (Jordi Rodón, Jordi Rodon)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 53

Top Topics

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

Nature medicine

JCO precision oncology

Cancer research communications

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Natalie Yan Li Ngoi, Tin-Yun Tang, Catia F Gaspar, Dean C Pavlick, Gregory M Buchold, Emma L Scholefield, Vamsi Parimi, Richard S P Huang, Tyler Janovitz, Natalie Danziger, Mia A Levy, Shubham Pant, Anaemy Danner De Armas, David Kumpula, Jeffery S Ross, Milind M Javle, Jordi Rodon Ahnert
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers. The oncologist (2024)
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Filip Janku, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Siqing Fu, David S Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer research communications 4 (2) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Camilla O Hoff, Eduardo Andreazza Dal Lago, Juliana Mota Siqueira, Luana Guimaraes de Sousa, Adel K El-Naggar, Jordi Rodon Ahnert, Renata Ferrarotto
First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report. JCO precision oncology 8 (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Carmen J Calfa, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Eugene R Ahn, Monika L Burness, Keerthi Gogineni, Nitin Rohatgi, Tareq Al Baghdadi, Alison Conlin, Anu Gaba, Omid Hamid, Jairam Krishnamurthy, Naga Jyothi Gavini, Philip J Gold, Jordi Rodon Ahnert, J Scott Roberts, Ramya Thota, Gina N Grantham, Dominique C Hinshaw, Abigail Gregory, Susan Halabi, Richard L Schilsky
Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO precision oncology 8 (2024)
Timothy P DiPeri, Kurt W Evans, Bailiang Wang, Ming Zhao, Argun Akcakanat, Maria Gabriela Raso, Yasmeen Q Rizvi, Xiaofeng Zheng, Anil Korkut, Kaushik Varadarajan, Burak Uzunparmak, Ecaterina E Ileana Dumbrava, Shubham Pant, Jaffer A Ajani, Paula R Pohlmann, Vanessa B Jensen, Milind M Javle, Jordi Rodon Ahnert, Funda Meric-Bernstam
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer discovery 14 (5) (2024)
Natalie Yan Li Ngoi, Tin-Yun Tang, Catia F Gaspar, Dean C Pavlick, Gregory M Buchold, Emma L Scholefield, Vamsi Parimi, Richard S P Huang, Tyler Janovitz, Natalie Danziger, Mia A Levy, Shubham Pant, Anaemy Danner De Armas, David Kumpula, Jeffery S Ross, Milind M Javle, Jordi Rodon Ahnert
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers. The oncologist 29 (6) (2024)
Nazanin K Majd, Henry Hiep Vo, Cesar A Moran, Shiao-Pei Weathers, I-Wen Song, Garret L Williford, Jordi Rodon Ahnert, Siqing Fu, Apostolia-Maria Tsimberidou
Metastatic extraneural glioblastoma diagnosed with molecular testing. The oncologist (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Camilla O Hoff, Eduardo Andreazza Dal Lago, Juliana Mota Siqueira, Luana Guimaraes de Sousa, Adel K El-Naggar, Jordi Rodon Ahnert, Renata Ferrarotto
First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report. JCO precision oncology 8 (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Timothy P DiPeri, Kurt W Evans, Bailiang Wang, Ming Zhao, Argun Akcakanat, Maria Gabriela Raso, Yasmeen Q Rizvi, Xiaofeng Zheng, Anil Korkut, Kaushik Varadarajan, Burak Uzunparmak, Ecaterina E Ileana Dumbrava, Shubham Pant, Jaffer A Ajani, Paula R Pohlmann, Vanessa B Jensen, Milind M Javle, Jordi Rodon Ahnert, Funda Meric-Bernstam
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer discovery 14 (5) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Brian Belmontes, Katherine K Slemmons, Chun Su, Siyuan Liu, Antonia N Policheni, Jodi Moriguchi, Hong Tan, Fang Xie, Daniel Andrew Aiello, Yajing Yang, Raul Lazaro, Famke Aeffner, Matthew G Rees, Melissa A Ronan, Jennifer A Roth, Mikkel Vestergaard, Sanne Cowland, Jan Andersson, Ian Sarvary, Qing Chen, Pooja Sharma, Patricia Lopez, Nuria A Tamayo, Liping H Pettus, Sudipa Ghimire-Rijal, Susmith Mukund, Jennifer R Allen, Jason DeVoss, Angela Coxon, Jordi Rodon Ahnert, François Ghiringhelli, Nicolas Penel, Hans Prenen, Sanne Glad, Chen-Hua Chuang, Kiana Keyvanjah, Danielle M Townsley, John R Butler, Matthew P Bourbeau, Sean Caenepeel, Paul E Hughes
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients With MTAP-Deleted Cancers. Cancer discovery (2024)
Natalie Yan Li Ngoi, Tin-Yun Tang, Catia F Gaspar, Dean C Pavlick, Gregory M Buchold, Emma L Scholefield, Vamsi Parimi, Richard S P Huang, Tyler Janovitz, Natalie Danziger, Mia A Levy, Shubham Pant, Anaemy Danner De Armas, David Kumpula, Jeffery S Ross, Milind M Javle, Jordi Rodon Ahnert
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers. The oncologist 29 (6) (2024)
Timothy P DiPeri, Kurt W Evans, Bailiang Wang, Ming Zhao, Argun Akcakanat, Maria Gabriela Raso, Yasmeen Q Rizvi, Xiaofeng Zheng, Anil Korkut, Kaushik Varadarajan, Burak Uzunparmak, Ecaterina E Ileana Dumbrava, Shubham Pant, Jaffer A Ajani, Paula R Pohlmann, Vanessa B Jensen, Milind M Javle, Jordi Rodon Ahnert, Funda Meric-Bernstam
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer discovery 14 (5) (2024)
Camilla O Hoff, Eduardo Andreazza Dal Lago, Juliana Mota Siqueira, Luana Guimaraes de Sousa, Adel K El-Naggar, Jordi Rodon Ahnert, Renata Ferrarotto
First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report. JCO precision oncology 8 (2024)
Timothy P DiPeri, Kurt W Evans, Bailiang Wang, Ming Zhao, Argun Akcakanat, Maria Gabriela Raso, Yasmeen Q Rizvi, Xiaofeng Zheng, Anil Korkut, Kaushik Varadarajan, Burak Uzunparmak, Ecaterina E Ileana Dumbrava, Shubham Pant, Jaffer A Ajani, Paula R Pohlmann, Vanessa B Jensen, Milind M Javle, Jordi Rodon Ahnert, Funda Meric-Bernstam
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer discovery 14 (5) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Camilla O Hoff, Eduardo Andreazza Dal Lago, Juliana Mota Siqueira, Luana Guimaraes de Sousa, Adel K El-Naggar, Jordi Rodon Ahnert, Renata Ferrarotto
First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report. JCO precision oncology 8 (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Timothy P DiPeri, Kurt W Evans, Bailiang Wang, Ming Zhao, Argun Akcakanat, Maria Gabriela Raso, Yasmeen Q Rizvi, Xiaofeng Zheng, Anil Korkut, Kaushik Varadarajan, Burak Uzunparmak, Ecaterina E Ileana Dumbrava, Shubham Pant, Jaffer A Ajani, Paula R Pohlmann, Vanessa B Jensen, Milind M Javle, Jordi Rodon Ahnert, Funda Meric-Bernstam
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer discovery 14 (5) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Natalie Yan Li Ngoi, Tin-Yun Tang, Catia F Gaspar, Dean C Pavlick, Gregory M Buchold, Emma L Scholefield, Vamsi Parimi, Richard S P Huang, Tyler Janovitz, Natalie Danziger, Mia A Levy, Shubham Pant, Anaemy Danner De Armas, David Kumpula, Jeffery S Ross, Milind M Javle, Jordi Rodon Ahnert
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers. The oncologist 29 (6) (2024)
Timothy P DiPeri, Kurt W Evans, Bailiang Wang, Ming Zhao, Argun Akcakanat, Maria Gabriela Raso, Yasmeen Q Rizvi, Xiaofeng Zheng, Anil Korkut, Kaushik Varadarajan, Burak Uzunparmak, Ecaterina E Ileana Dumbrava, Shubham Pant, Jaffer A Ajani, Paula R Pohlmann, Vanessa B Jensen, Milind M Javle, Jordi Rodon Ahnert, Funda Meric-Bernstam
Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer discovery (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Filip Janku, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Siqing Fu, David S Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer research communications 4 (2) (2024)
Jibran Ahmed, Carlos Torrado, Anca Chelariu-Raicu, Sun-Hee Kim, Jordi Rodon Ahnert
Fusion Challenges in Solid Tumors: Shaping the Landscape of Cancer Care in Precision Medicine. JCO precision oncology 8 (2024)
Camilla O Hoff, Eduardo Andreazza Dal Lago, Juliana Mota Siqueira, Luana Guimaraes de Sousa, Adel K El-Naggar, Jordi Rodon Ahnert, Renata Ferrarotto
First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report. JCO precision oncology 8 (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Roberto Carmagnani Pestana, Justin Tyler Moyers, Jason Roszik, Shiraj Sen, David S Hong, Aung Naing, Cynthia E Herzog, Siqing Fu, Sarina A Piha-Paul, Jordi Rodon Ahnert, Timothy Anthony Yap, Daniel D Karp, Apostolia-Maria Tsimberidou, Shubham Pant, Maria Alejandra Zarzour, Ravin Ratan, Vinod Ravi, Robert S Benjamin, Alexander J F Lazar, Wei-Lien Wang, Najat C Daw, Jonathan D Gill, Douglas J Harrison, Valerae O Lewis, Christina Lynn Roland, Shreyaskumar R Patel, Jonathan A Livingston, Neeta Somaiah, Joseph A Ludwig, Anthony P Conley, Nelson Hammerschlak, Richard G Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Glenn J Hanna, Anastasios Stathis, Elena Lopez-Miranda, Fabricio Racca, Doris V Quon, Serge Leyvraz, Dagmar Hess, Bhumsuk Keam, Jordi Rodon Ahnert, Myung-Ju Ahn, Hye Ryun Kim, Andreas Schneeweiß, Josep-María Ribera, Daniel J DeAngelo, Jose Manuel Perez Garcia, Javier Cortes, Oliver Schönborn-Kellenberger, Dirk Weber, Pavel Pisa, Michael Bauer, Laura Beni, Maria Bobadilla, Raj Lehal, Michele Vigolo, Florian D Vogl, Elena Garralda
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors. Cancer research communications 3 (9) (2023)
Anthony B El-Khoueiry, James Clarke, Tobias Neff, Tim Crossman, Nirav Ratia, Chetan Rathi, Paul Noto, Aarti Tarkar, Ignacio Garrido-Laguna, Emiliano Calvo, Jordi Rodon Ahnert, Ben Tran, Peter J O'Dwyer, Adam Cuker, Albiruni R Abdul Razak
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors. British journal of cancer (2023)
Lars D Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, David Trinh, Allan Hebbert, Christopher R Smith, Svitlana Kulyk, J David Lawson, Quanyuan He, Laura D Hover, Julio Fernandez-Banet, Jill Hallin, Darin Vanderpool, David M Briere, Alice Blaj, Matthew A Marx, Jordi Rodon Ahnert, Michael D Offin, Kathryn C Arbour, Melissa Lynne Johnson, David J Kwiatkowski, Pasi A Janne, Candace L Haddox, Kyriakos P Papadopoulos, Jason T Henry, Konstantinos Leventakos, James G Christensen, Ronald Shazer, Peter Olson
MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer. Cancer discovery (2023)
Ryan A Denu, Richard K Yang, Alexander J F Lazar, Shalin S Patel, Valerae O Lewis, Jason Roszik, Jonathan A Livingston, Wei-Lien Wang, Kenna Rael Shaw, Ravin Ratan, Maria Alejandra Zarzour, Justin E Bird, Shaan M Raza, Kadir C Akdemir, Jordi Rodon Ahnert, Vivek Subbiah, Shreyaskumar R Patel, Anthony P Conley
Clinico-genomic profiling of conventional and dedifferentiated chondrosarcomas reveals TP53 mutation to be associated with worse outcomes. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Tin-Yun Tang, Federico Nichetti, Benjamin Kaplan, Sara Lonardi, Filippo Pietrantonio, Lisa Salvatore, Caterina Vivaldi, Lorenza Rimassa, Filippo G De Braud, Mario Domenico Rizzato, Dean C Pavlick, Randy Chu, Anaemy Danner De Armas, Radwa Sharaf, Ethan S Sokol, Jordi Rodon Ahnert, Jeffery S Ross, Milind M Javle, Monica Niger
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Herbert L Duvivier, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Eugene R Ahn, Tareq Al Baghdadi, Ajjai S Alva, Stephanie A Dublis, Timothy L Cannon, Carmen J Calfa, Rui Li, Deepti Behl, Vi K Chiu, Philip J Gold, Alissa S Marr, Kathryn F Mileham, Steven Francis Powell, Jordi Rodon Ahnert, Ramya Thota, Gina N Grantham, Abigail Gregory, Dominique C Hinshaw, Susan Halabi, Richard L Schilsky
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Juanita Lopez, Julia Lai-Kwon, Rhoda Molife, Liam Welsh, Nina Tunariu, Desamparados Roda, Paula Fernández-García, Victoria Lladó, Adrian G McNicholl, Catalina A Rosselló, Richard J Taylor, Analía Azaro, Jordi Rodon Ahnert, Julieann Sludden, Gareth J Veal, Ruth Plummer, Ander Urruticoechea, Ainhara Lahuerta, Karmele Mujika, Pablo V Escribá
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma. British journal of cancer (2023)
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Filip Janku, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Siqing Fu, David S Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Phase I study of mTORC1/2 inhibitor sapanisertib in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. Cancer research communications (2023)
Benjamin Garmezy, Jinesh S Gheeya, Heather Y Lin, Yuefan Huang, Taebeom Kim, Xian-Li Jiang, Kyaw Zin Thein, Patrick G Pilié, Fadl Zeineddine, Wanlin Wang, Kenna Rael Shaw, Jordi Rodon Ahnert, John Paul Shen, Ying Yuan, Funda Meric-Bernstam, Ken Chen, Timothy A Yap
Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO precision oncology 6 (2022)
Justin Tyler Moyers, Roberto Carmagnani Pestana, Jason Roszik, David S Hong, Aung Naing, Siqing Fu, Sarina A Piha-Paul, Timothy Anthony Yap, Daniel D Karp, Jordi Rodon Ahnert, Jonathan A Livingston, Maria Alejandra Zarzour, Vinod Ravi, Shreyaskumar R Patel, Robert S Benjamin, Joseph A Ludwig, Cynthia E Herzog, Ravin Ratan, Neeta Somaiah, Anthony P Conley, Richard G Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Jordi Rodon Ahnert, Pauline Funchain, Theodore W Laetsch, Hendrick-Tobias Arkenau, Alice Hervieu, Christian F Singer, Yonina R Murciano-Goroff, Sant P Chawla, Kristin Anthony, Ikuo Yamamiya, Mei Liu, Abdel-Baset Halim, Karim A Benhadji, Osamu Takahashi, Suzette Delaloge
A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN -inactivating mutations. Future oncology (London, England) 18 (30) (2022)
Mohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, S Greg Call, Daniel D Karp, Siqing Fu, Aung Naing, Vivek Subbiah, Shubham Pant, Derek J Dustin, Apostolia-Maria Tsimberidou, David S Hong, Jordi Rodon Ahnert, Funda Meric-Bernstam, Filip Janku
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO precision oncology 6 (2022)
Tito R Mendoza, David S Hong, Christine B Peterson, Bettzy Stephen, Ecaterina Dumbrava, Shubbam Pant, Apostolia Maria Tsimberidou, Timothy Anthony Yap, Ajay Sheshadri, Mehmet Altan, Goldy George, Lilibeth Castillo, Enedelia Rodriguez, Jing Gong, Vivek Subbiah, Filip Janku, Siqing Fu, Sarina A Piha-Paul, Jordi Rodon Ahnert, Daniel D Karp, Charles Cleeland, Funda Meric-Bernstam, Aung Naing
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Scientific reports 12 (1) (2022)
Siqing Fu, Shuyang Yao, Yuan Yuan, Rebecca Ann Previs, Anthony D Elias, Richard D Carvajal, Thomas J George, Ying Yuan, Lihou Yu, Shannon Neville Westin, Yan Xing, Ecaterina E Ileana Dumbrava, Daniel D Karp, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Jordi Rodon Ahnert, Naoko Takebe, Karen H Lu, Khandan Keyomarsi, Funda Meric-Bernstam
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Jordi Rodon Ahnert, Guillem Argilés, Roisin M Connolly, Ulka Vaishampayan, Maja de Jonge, Elena Garralda, Marios Giannakis, David C Smith, Jason R Dobson, Margaret E McLaughlin, Abdelkader Seroutou, Yan Ji, Jennifer Morawiak, Susan E Moody, Filip Janku
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. British journal of cancer 125 (1) (2021)